Targeting the Clinical, Economic and Payer Considerations of Atopic Dermatitis

An overview of what has been learned over time that can help dermatologists and other community physicians appropriately identify signs of atopic dermatitis in children and adults.

The impact atopic dermatitis and associated comorbidities have on patients with the condition, as well as family members.

Indirect costs associated with atopic dermatitis, and the financial burden associated with delayed treatment initiation or inappropriate therapy.

Considerations for quality measures established for atopic dermatitis when assessing how well patients are responding to treatment.

An overview of topical and oral therapies used to treat mild-to-moderate atopic dermatitis.

Variables considered when developing and referring to treatment formularies for atopic dermatitis.

Dr Lio discusses features that make JAK inhibitors, including ruxolitinib, abrocitinib, baricitinib, and upadacitinib, attractive in the management of atopic dermatitis.

Drs Shah and Lio explore where topical ruxolitinib fits into therapeutic sequencing in atopic dermatitis, compared with oral JAK inhibitors.

An overview of limitations faced by payers and clinicians who play a role in the management of atopic dermatitis.

Payer and clinician insight regarding access to effective therapies for atopic dermatitis and potential challenges adopting new therapies, including topical JAK inhibitors, into clinical practice.

Current strategies used to evaluate the performance of therapies used to treat atopic dermatitis and guide formulary decisions, and recommendations to help patients receive access to effective therapies.